Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma

CHIKARA KUNISAKI, TOSHIO IMADA, ROPPEI YAMADA, SHINSUKE HATORI, HIDETAKA ONO, YUICHI OTSUKA, GORO MATSUDA, MASATO NOMURA, HIROTOSHI AKIYAMA, AKIRA KUBO and HIROSHI SHIMADA
Anticancer Research July 2005, 25 (4) 2973-2977;
CHIKARA KUNISAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: s0714@med.yokohama-cu.ac.jp
TOSHIO IMADA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROPPEI YAMADA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINSUKE HATORI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDETAKA ONO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUICHI OTSUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GORO MATSUDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATO NOMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTOSHI AKIYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIRA KUBO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI SHIMADA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. Patients and Methods: Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m2 of docetaxel followed by 60 mg/m2 of cisplatin. This regimen was repeated at least three times at 3-week intervals. Results: The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median survival time was 13 months from the start of the first-line therapy and 6 months from the second-line therapy. With respect to toxicity, the major adverse effect was leukopenia, which reached grades 3-4 in 26.7%. Non-hematological toxicities were usually moderate, and no deaths were attributable to the adverse effects of the drugs. Conclusion: This combination therapy was effective as a second-line treatment for advanced gastric cancer with acceptable toxic side-effects.

  • Advanced gastric cancer
  • cisplatin
  • docetaxel
  • TS-1
  • phase II study
  • second-line chemotherapy

Footnotes

  • Received February 9, 2005.
  • Accepted May 5, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma
CHIKARA KUNISAKI, TOSHIO IMADA, ROPPEI YAMADA, SHINSUKE HATORI, HIDETAKA ONO, YUICHI OTSUKA, GORO MATSUDA, MASATO NOMURA, HIROTOSHI AKIYAMA, AKIRA KUBO, HIROSHI SHIMADA
Anticancer Research Jul 2005, 25 (4) 2973-2977;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma
CHIKARA KUNISAKI, TOSHIO IMADA, ROPPEI YAMADA, SHINSUKE HATORI, HIDETAKA ONO, YUICHI OTSUKA, GORO MATSUDA, MASATO NOMURA, HIROTOSHI AKIYAMA, AKIRA KUBO, HIROSHI SHIMADA
Anticancer Research Jul 2005, 25 (4) 2973-2977;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Modified Docetaxel-cisplatin in Combination with Capecitabine as First-line Treatment in Metastatic Gastric Cancer. A Phase II Study
  • The Role of Chemotherapy in Metastatic Gastric Cancer
  • Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric Cancer
  • Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents?
  • Google Scholar

More in this TOC Section

  • Primary Synovial Sarcoma of the Bone: A Case Report and Literature Review
  • Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019
  • Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire